CONMED Corporation Common Stock (CNMD)
StalwartFairStock Score: 38/100 — MIXED
Key Financials
| Current Price | $35.49 |
| Market Cap | $1.2B |
| P/E Ratio | 20.05 |
| ROE | 5.5% |
| Dividend Yield | 2.28% |
| Sector | Healthcare |
Strengths
- Generates $169 million in annual free cash flow (14.4% yield on market cap)
- Strong Piotroski F-Score of 8/9 indicating robust financial health across profitability, leverage, and efficiency metrics
- Attractive 2.1% dividend yield providing steady income returns
Concerns
- Altman Z-Score of 1.3 places it in the financial distress zone—elevated bankruptcy risk
AI Analysis
CONMED Corporation Common Stock is a micro-cap healthcare company valued at $1.2 billion. The business generates $1.4 billion in annual revenue with a 1.2% net margin and $169 million in free cash flow. From a quality standpoint, CONMED shows near-perfect Piotroski F-Score of 8/9 indicating exceptional financial health and distressed Altman Z-Score of 1.3 warrants caution. On valuation, the stock is reasonably priced at 24.8x earnings, with trades above its Graham Number with a negative 13% margin. Growth dynamics show revenue growing at 7.9% and profit growth of -50.4%. The 2.1% dividend yield adds an income component for patient holders. Our composite FairStock Score of 38/100 reflects below-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.
Bull Case
Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. With $169 million in annual free cash flow (14.4% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.
Bear Case
Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.
Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer